New Delhi, February 7
Melting of Himalayan glaciers has doubled since the start of the 21st century due to rising temperatures, losing over a vertical foot and half of ice each year and potentially
Share this article
Share this article
DAEJEON, South Korea, Feb. 1, 2021 /PRNewswire/ ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal
Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865). The study showed successful results in preventing preterm birth and improving the fetus viability with ILB-202, ILIAS s anti-inflammatory exosomes developed through its EXPLOR® platform technology.
This study result is the second proof of concept that suggests significant anti-inflammatory effects of the same exosome (ILB202) from ILIAS Biologics, Inc. In April 2020, the researchers at the Korea Advanced Institute of Science and Technology (KAIST) and the ILIAS team published the same exosome s substantial efficacy in the septic mouse model in
Researchers making the list were identified as scientists who are influencing the future direction of their respective fields. Fewer than 0.1% of the world’s researchers, across 22 research fields, have earned this exclusive distinction.
Shidler Professor Stephen Vargo
This is Vargo’s seventh consecutive year named to the list in the business and economics discipline. Vargo earned the recognition by demonstrating exceptional influence through his publications, which were frequently cited by his peers during the last decade. His articles focused on the “Service-Dominant (
S-D) Logic” framework, which redefines how value is co-created through economic exchange.
“We are extremely proud of Professor Vargo. He is an excellent researcher and mentor to our doctoral students as well as our junior faculty,” Shidler College of Business Dean